Ítem
Solo Metadatos

Buprenorphine 5, 10 and 20?gh transdermal patch: A review of its use in the management of chronic non-malignant pain

Mostrar el registro sencillo de la publicación
dc.creatorPlosker G.L.spa
dc.creatorBarkin R.L.spa
dc.creatorBreivik H.spa
dc.creatorGordon A.spa
dc.creatorHernandez J.J.spa
dc.creatorHess P.E.spa
dc.date.accessioned2020-05-26T00:06:14Z
dc.date.available2020-05-26T00:06:14Z
dc.date.created2011spa
dc.description.abstractThis article reviews the pharmacology, therapeutic efficacy and tolerability profile of the 7-day lower-dose (5, 10 and 20?gh) buprenorphine transdermal patch (BuTrans®, Norspan®) in the management of chronic non-malignant pain, with a focus on European labelling for the drug. Buprenorphine is a semi-synthetic opioid analgesic that acts primarily as a partial agonist at the mu opioid receptor. The transdermal formulation provides continuous delivery of buprenorphine, resulting in relatively consistent plasma drug concentrations throughout the 7-day dosing interval.The analgesic efficacy of transdermal buprenorphine in patients with osteoarthritis of the hip andor knee has been demonstrated in several randomized controlled trials, which have shown the formulation to be equivalent to sublingual buprenorphine, noninferior to prolonged-release tramadol tablets, noninferior to codeine plus paracetamol (acetaminophen) combination tablets (when transdermal buprenorphine was used together with regularly scheduled oral paracetamol) and generally superior to a matching transdermal placebo patch. Transdermal buprenorphine was significantly more effective than placebo in reducing chronic low back pain of at least moderate severity in two randomized, double-blind, crossover trials. Other clinical trials, including a randomized, double-blind, maintenance-of-analgesia study, have also demonstrated the analgesic efficacy of transdermal buprenorphine in patients with chronic non-malignant pain of various causes.In general, serious adverse events with transdermal buprenorphine are similar to those for other opioid analgesics. Transdermal buprenorphine has a ceiling effect for respiratory depression, and the main risk is when it is combined with other CNS depressants. The most frequently reported adverse events with transdermal buprenorphine are headache, dizziness, somnolence, constipation, dry mouth, nausea, vomiting, pruritus, erythema, application site pruritus and application site reactions. Transdermal buprenorphine was better tolerated than sublingual buprenorphine in a 7-week, randomized, double-blind trial in patients with osteoarthritis pain. Nevertheless, as with other opioids, persistence with transdermal buprenorphine therapy is difficult for many patients because of adverse events or other reasons.Thus, transdermal buprenorphine has generally demonstrated good efficacy and tolerability in clinical trials in chronic non-malignant pain, providing effective background analgesia as part of pain management strategies for patients with osteoarthritis, low back pain and other persistent pain syndromes of at least moderate severity. It also has favourable pharmacodynamic and pharmacokinetic properties, which have beneficial clinical implications, most notably the convenience of once-weekly administration and no need for dosage adjustments in the elderly or those with compromised renal function, making it an opioid of choice in these patients, and a useful therapeutic option overall in the management of chronic non-malignant pain. © 2011 Adis Data Information BV. All rights reserved.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.2165/11208250-000000000-00000
dc.identifier.issn126667
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23870
dc.language.isoengspa
dc.publisherSpringer International Publishingspa
dc.relation.citationEndPage2509
dc.relation.citationIssueNo. 18
dc.relation.citationStartPage2491
dc.relation.citationTitleDrugs
dc.relation.citationVolumeVol. 71
dc.relation.ispartofDrugs, ISSN:126667, Vol.71, No.18 (2011); pp. 2491-2509spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-82955172932&doi=10.2165%2f11208250-000000000-00000&partnerID=40&md5=e56f9c0a949cb07615d0480bf64bab28spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAtazanavirspa
dc.subject.keywordBuprenorphinespa
dc.subject.keywordCarbamazepinespa
dc.subject.keywordCentral depressant agentspa
dc.subject.keywordCodeinespa
dc.subject.keywordCyclooxygenase 2 inhibitorspa
dc.subject.keywordDiclofenacspa
dc.subject.keywordDihydrocodeinespa
dc.subject.keywordEfavirenzspa
dc.subject.keywordHalothanespa
dc.subject.keywordIbuprofenspa
dc.subject.keywordKetoconazolespa
dc.subject.keywordMu opiate receptorspa
dc.subject.keywordNaloxonespa
dc.subject.keywordNonsteroid antiinflammatory agentspa
dc.subject.keywordNorspanspa
dc.subject.keywordOxycodonespa
dc.subject.keywordParacetamolspa
dc.subject.keywordPhenobarbitalspa
dc.subject.keywordPhenytoinspa
dc.subject.keywordRifampicinspa
dc.subject.keywordRitonavirspa
dc.subject.keywordTilidinespa
dc.subject.keywordTramadolspa
dc.subject.keywordUnclassified drugspa
dc.subject.keywordApplication site pruritusspa
dc.subject.keywordApplication site reactionspa
dc.subject.keywordChronic painspa
dc.subject.keywordClinical trial (topic)spa
dc.subject.keywordConstipationspa
dc.subject.keywordControlled clinical trial (topic)spa
dc.subject.keywordCrossover procedurespa
dc.subject.keywordDisease registryspa
dc.subject.keywordDisease severityspa
dc.subject.keywordDizzinessspa
dc.subject.keywordDouble blind procedurespa
dc.subject.keywordDrug blood levelspa
dc.subject.keywordDrug dosage form comparisonspa
dc.subject.keywordDrug dose titrationspa
dc.subject.keywordDrug efficacyspa
dc.subject.keywordDrug eliminationspa
dc.subject.keywordDrug formulationspa
dc.subject.keywordDrug interactionspa
dc.subject.keywordDrug metabolismspa
dc.subject.keywordDrug tolerancespa
dc.subject.keywordDrug withdrawalspa
dc.subject.keywordEmbasespa
dc.subject.keywordErythemaspa
dc.subject.keywordGastrointestinal diseasespa
dc.subject.keywordHeadachespa
dc.subject.keywordHip osteoarthritisspa
dc.subject.keywordHumanspa
dc.subject.keywordKnee osteoarthritisspa
dc.subject.keywordLoading drug dosespa
dc.subject.keywordLow back painspa
dc.subject.keywordLow drug dosespa
dc.subject.keywordNauseaspa
dc.subject.keywordNonhumanspa
dc.subject.keywordPruritusspa
dc.subject.keywordPublicationspa
dc.subject.keywordRandomized controlled trial (topic)spa
dc.subject.keywordRespiration depressionspa
dc.subject.keywordReviewspa
dc.subject.keywordSomnolencespa
dc.subject.keywordTransdermal patchspa
dc.subject.keywordVomitingspa
dc.subject.keywordXerostomiaspa
dc.subject.keywordAdis-drug-evaluationsspa
dc.subject.keywordBuprenorphinespa
dc.subject.keywordPainspa
dc.subject.keywordTransdermalspa
dc.titleBuprenorphine 5, 10 and 20?gh transdermal patch: A review of its use in the management of chronic non-malignant painspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos